{"preliminary_commentary":{"by_channel":{"x_thread":26,"youtube":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06059547\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"GDFATHER-NEO","nct_id":"NCT06059547","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=gdfather-neo-nct06059547. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Placebo + Checkpoint Inhibitor nivolumab","label":"Combination with Placebo","type":"ACTIVE_COMPARATOR"},{"description":"visugromab (CTL-002) + Checkpoint Inhibitor nivolumab","label":"Combination with Visugromab/Verum","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-06-05","type":"ACTUAL"},"conditions":["Bladder Cancer","Adult Solid Tumor"],"enrollment":{"count":31,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab","otherNames":[],"type":"DRUG"},{"name":"Visugromab (CTL-002)","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-19","lead_sponsor":"CatalYm GmbH","official_title":"A Multi-center Phase 2 Study of Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for the Treatment of Muscle Invasive Bladder Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-10-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Pathological complete response rate","timeFrame":"min. 4 months"},{"measure":"Radiological response rate according RECIST","timeFrame":"min. 4 months"}],"references":[{"citation":"Necchi A, Mercinelli C, Maiorano BA, Piacentini M, Cigliola A, Iacovelli R, Ciccarese C, Ligato C, Giannatempo P, Rametta A, Gontero P, Soria F, Schuberth-Wagner C, Wischhusen J, Rossler B, Metterlein M, Ries S, Ross T, Amin A, Dreker T, Hermann F, Lemke L, Klar K, Mitina O, Kamova A, Fettes P, Auckenthaler A, Rao S, Leo E, Lichtenegger FS. Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial. Nat Med. 2026 Oct 24. doi: 10.1038/s41591-026-04740-9. Online ahead of print.","pmid":"42926233","type":"DERIVED"}],"start_date":{"date":"2023-09-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT06059547"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/gdfather-neo-nct06059547"}